140 related articles for article (PubMed ID: 1682372)
1. Enterococcus faecium sensitive to teicoplanin but not vancomycin.
Wilson AP; Felmingham D; Robbins M; Chopra R
J Hosp Infect; 1991 Aug; 18(4):322-4. PubMed ID: 1682372
[No Abstract] [Full Text] [Related]
2. Gram-positive infections in neutropenic patients: glycopeptide antibiotic choice.
Menichetti F
J Antimicrob Chemother; 1992 Apr; 29(4):461-3. PubMed ID: 1535070
[No Abstract] [Full Text] [Related]
3. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
[TBL] [Abstract][Full Text] [Related]
4. Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study.
Echeverria-Esnal D; Sorli L; Prim N; Conde-Estévez D; Mateu-De Antonio J; Martin-Ontiyuelo C; Horcajada JP; Grau S
Int J Antimicrob Agents; 2019 Nov; 54(5):572-578. PubMed ID: 31476435
[TBL] [Abstract][Full Text] [Related]
5. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus.
Torney HL; Balistreri FJ; Kenny MT; Cheng WD
J Antimicrob Chemother; 1991 Aug; 28(2):261-9. PubMed ID: 1838105
[TBL] [Abstract][Full Text] [Related]
6. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M
J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients.
Koc Y; Snydman DR; Schenkein DS; Miller KB
Bone Marrow Transplant; 1998 Jul; 22(2):207-9. PubMed ID: 9707033
[TBL] [Abstract][Full Text] [Related]
8. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
9. [Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
Klare I; Witte W
Wien Klin Wochenschr; 1997 May; 109(9):293-300. PubMed ID: 9265387
[No Abstract] [Full Text] [Related]
10. Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: posthoc analysis of a nationwide surveillance.
Ha S; Huh K; Chung DR; Ko JH; Cho SY; Huh HJ; Lee NY; Kang CI; Peck KR; Song JH;
Int J Infect Dis; 2022 Sep; 122():506-513. PubMed ID: 35752376
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
12. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
Nailor MD; Sobel JD
Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
[TBL] [Abstract][Full Text] [Related]
13. Teicoplanin in the treatment of serious infection.
Schaison G; Graninger W; Bouza E
J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
[TBL] [Abstract][Full Text] [Related]
14. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.
Chow JW; Donahedian SM; Zervos MJ
Clin Infect Dis; 1997 Jan; 24(1):90-1. PubMed ID: 8994759
[No Abstract] [Full Text] [Related]
15. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
Noskin GA; Siddiqui F; Stosor V; Kruzynski J; Peterson LR
Clin Infect Dis; 1999 Mar; 28(3):689-90. PubMed ID: 10194104
[No Abstract] [Full Text] [Related]
17. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.
Edmond MB; Ober JF; Weinbaum DL; Pfaller MA; Hwang T; Sanford MD; Wenzel RP
Clin Infect Dis; 1995 May; 20(5):1126-33. PubMed ID: 7619987
[TBL] [Abstract][Full Text] [Related]
18. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.
Linden PK; Pasculle AW; Manez R; Kramer DJ; Fung JJ; Pinna AD; Kusne S
Clin Infect Dis; 1996 Apr; 22(4):663-70. PubMed ID: 8729206
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.
Borja J; Gratacós L; García-Barbal J
J Infect Dis; 1994 Nov; 170(5):1344-5. PubMed ID: 7963743
[No Abstract] [Full Text] [Related]
20. Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus.
Cunningham R
J Antimicrob Chemother; 1992 Apr; 29(4):459-6. PubMed ID: 1535069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
